Literature DB >> 26171175

Comparison of the clinicopathological behavior of the follicular variant of papillary thyroid carcinoma and classical papillary thyroid carcinoma: A systematic review and meta-analysis.

Jing Yang1, Yanping Gong1, Shuping Yan1, Qingquan Shi2, Jingqiang Zhu1, Zhihui Li1, Qiang Chen1, Rixiang Gong1.   

Abstract

The follicular variant of papillary thyroid carcinoma (FV-PTC) is the second most common type of papillary thyroid carcinoma (PTC), and it has been increasingly diagnosed in recent years. However, whether FV-PTC behaves differently from classical PTC (C-PTC) remains controversial. To address this controversy, a meta-analysis was performed to determine the potential differences between FV-PTC and C-PTC in their clinicopathological behavior. The relevant published studies between January 1, 2003 and August 31, 2014 were reviewed according to the defined selection criteria using the PubMed database. Review Manager was used to calculate the pooled odds ratio (OR) or the mean difference (MD) with a 95% confidence interval (CI), using a random- or fixed-effect model for all analyses. In total, 112 studies were identified and examined; finally, only 36 studies met the inclusion criteria. In the 36 studies, compared to the clinicopathological behavior of patients with C-PTC, patients with FV-PTC had the following parameters: Similar mean age and similar prevalence of gender, tumor size ≥10 mm, multifocality, capsular invasion, vascular invasion, lymphocytic and/or Hashimoto's thyroiditis, and clinical stage; a larger mean tumor size and higher prevalence of age ≥45 years; and lower prevalence of extrathyroidal extensions, lymph node metastases, BRAF mutation and recurrence. The meta-analysis suggested that patients with FV-PTC have a more favorable clinicopathological behavior and improved prognosis compared to patients with C-PTC. Thus, patients with FV-PTC and C-PTC may be managed differently, and the two types of PTC should be clearly distinguished in future retrospective or prospective studies.

Entities:  

Keywords:  classical; follicular; meta-analysis; papillary; thyroid carcinoma

Year:  2015        PMID: 26171175      PMCID: PMC4487034          DOI: 10.3892/mco.2015.540

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  56 in total

1.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

2.  Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up.

Authors:  Philippe Hagag; Nir Hod; Esther Kummer; Mehrzad Cohenpour; Tifha Horne; Mordechai Weiss
Journal:  Cancer J       Date:  2006 Jul-Aug       Impact factor: 3.360

3.  Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas.

Authors:  Hung-Yu Chang; Jen-Der Lin; Shuo-Chi Chou; Tzu-Chieh Chao; Chuen Hsueh
Journal:  Jpn J Clin Oncol       Date:  2006-09-25       Impact factor: 3.019

4.  Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?

Authors:  Sandra Lassalle; Véronique Hofman; Marius Ilie; Christelle Bonnetaud; Marie-Pierre Puisségur; Patrick Brest; Céline Loubatier; Nicolas Guevara; Olivier Bordone; Bruno Cardinaud; Kévin Lebrigand; Géraldine Rios; Joseph Santini; Brigitte Franc; Bernard Mari; Abir Al Ghuzlan; Philippe Vielh; Pascal Barbry; Paul Hofman
Journal:  Endocr Relat Cancer       Date:  2011-09-13       Impact factor: 5.678

5.  Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival.

Authors:  Jamal Zidan; Drumea Karen; Moshe Stein; Edward Rosenblatt; Walid Basher; Abraham Kuten
Journal:  Cancer       Date:  2003-03-01       Impact factor: 6.860

6.  Follicular variant of papillary thyroid carcinoma. A clinicopathologic study.

Authors:  E T Tielens; S I Sherman; R H Hruban; P W Ladenson
Journal:  Cancer       Date:  1994-01-15       Impact factor: 6.860

7.  BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Authors:  Angela M Costa; Agustín Herrero; Manuel F Fresno; Jonas Heymann; José Antonio Alvarez; Jose Cameselle-Teijeiro; Ginesa García-Rostán
Journal:  Clin Endocrinol (Oxf)       Date:  2007-12-05       Impact factor: 3.478

8.  High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.

Authors:  Gisele Oler; Janete M Cerutti
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

9.  Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern).

Authors:  Michael Rivera; R Michael Tuttle; Snehal Patel; Ashok Shaha; Jatin P Shah; Ronald A Ghossein
Journal:  Thyroid       Date:  2009-02       Impact factor: 6.568

10.  BRAF mutations in thyroid tumors from an ethnically diverse group.

Authors:  Hans-Juergen Schulten; Sherine Salama; Zuhoor Al-Mansouri; Reem Alotibi; Khalid Al-Ghamdi; Osman Abdel Al-Hamour; Hassan Sayadi; Hosam Al-Aradati; Adel Al-Johari; Etimad Huwait; Mamdooh Gari; Mohammed Hussain Al-Qahtani; Jaudah Al-Maghrabi
Journal:  Hered Cancer Clin Pract       Date:  2012-08-27       Impact factor: 2.857

View more
  4 in total

1.  Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.

Authors:  Nathalie Chereau; Etienne Dauzier; Gaëlle Godiris-Petit; Séverine Noullet; Isabelle Brocheriou; Laurence Leenhardt; Camille Buffet; Fabrice Menegaux
Journal:  Langenbecks Arch Surg       Date:  2018-02-14       Impact factor: 3.445

2.  Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer.

Authors:  Sunghwan Suh; Tae Sik Goh; Yun Hak Kim; Sae-Ock Oh; Kyoungjune Pak; Ju Won Seok; In Joo Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

3.  Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma.

Authors:  Lauren E Henke; John D Pfeifer; Thomas J Baranski; Todd DeWees; Perry W Grigsby
Journal:  Endocr Connect       Date:  2018-12-01       Impact factor: 3.335

4.  Prevalence of BRAFV600E Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAFV600E Prevalent Area.

Authors:  Hyereen Kim; Bo Hyun Kim; Young Keum Kim; Jeong Mi Kim; Seo Young Oh; Eun Heui Kim; Min Jin Lee; Jong Ho Kim; Yun Kyung Jeon; Sang Soo Kim; Byung Joo Lee; Yong Ki Kim; In Joo Kim
Journal:  J Korean Med Sci       Date:  2018-01-24       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.